Routine serum calcitonin measurement in the evaluation of thyroid nodules

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 22, Issue 6, 2008, Pages 941-953

  Elisei, Rossella ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

calcitonin; calcium test; medullary thyroid carcinoma; pentagastrin test; thyroid nodule

Indexed keywords

CALCITONIN; GLUCONATE CALCIUM; PENTAGASTRIN; TUMOR MARKER;

ASPIRATION CYTOLOGY; BLURRED VISION; CALCITONIN BLOOD LEVEL; CANCER STAGING; CHILL; CLINICAL PRACTICE; COST BENEFIT ANALYSIS; CYTOPATHOLOGY; DIFFERENTIAL DIAGNOSIS; DIZZINESS; DROWSINESS; DRUG INDUCED HEADACHE; DYSPNEA; ENDOCRINE FUNCTION TEST; FALSE POSITIVE RESULT; FATIGUE; FLUSHING; HEALTH CARE COST; HEART ARRHYTHMIA; HORMONE ACTION; HORMONE DETERMINATION; HUMAN; HYPERCALCITONINEMIA; LIMB WEAKNESS; LYMPHADENECTOMY; MALIGNANT TRANSFORMATION; METABOLIC DISORDER; NODULAR GOITER; PAIN; PARESTHESIA; PREOPERATIVE EVALUATION; REVIEW; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; SKIN TINGLING; SWEATING; SYNCOPE; THYROID MEDULLARY CARCINOMA; THYROID NODULE; THYROIDECTOMY; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT;

CALCITONIN; CARCINOMA, MEDULLARY; HUMANS; THYROID NODULE; TUMOR MARKERS, BIOLOGICAL;

EID: 56649085318     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beem.2008.09.008     Document Type: Review

References (72)

1. Deftos L.J., Lee M.R., and Potts Jr. J.T. A radioimmunoassay for thyrocalcitonin. Proceedings of the National Academy of Sciences of the United States of America 60 (1968) 293-299
2. Tashjian Jr. A.H. Immunoassay of thyrocalcitonin. I. The method and its serological specificity. Endocrinology 84 (1969) 140-148
3. Przepiorka D., Baylin S.B., McBride O.W., et al. The human calcitonin gene is located on the short arm of chromosome 11. Biochemical and Biophysical Research Communications 120 (1984) 493-499
4. Hoppener J.W., Steenbergh P.H., Zandberg J., et al. The second human calcitonin/CGRP gene is located on chromosome 11. Human Genetics 70 (1985) 259-263
5. Cooper C.W., Deftos L.J., and Potts Jr. J.T. Direct measurement of in vivo secretion of pig thyrocalcitonin by radioimmunoassay. Endocrinology 88 (1971) 747-754
6. Emmertsen K.K., Nielsen H.E., Mosekilde L., et al. Pentagastrin, calcium and whisky stimulated serum calcitonin in medullary carcinoma of the thyroid. Acta Radiologica. Oncology 19 (1980) 85-89
7. Vitale G., Ciccarelli A., Caraglia M., et al. Comparison of two provocative tests for calcitonin in medullary thyroid carcinoma: omeprazole vs pentagastrin. Clinical Chemistry 48 (2002) 1505-1510
8. Oishi S., Yamauchi J., Fujimoto Y., et al. Calcitonin release from medullary thyroid carcinoma by thyrotropin-releasing hormone: comparison with calcium injection. Acta Endocrinologica 126 (1992) 325-328
9. Lin H.Y., Harris T.L., Flannery M.S., et al. Expression cloning of an adenylate cyclase-coupled calcitonin receptor. Science 254 (1991) 1022-1024
10. Hoff A.O., Catala-Lehnen P., Thomas P.M., et al. Increased bone mass is an unexpected phenotype associated with deletion of the calcitonin gene. The Journal of Clinical Investigation 110 (2002) 1849-1857
11. Deftos L.J., and First B.P. Calcitonin as a drug. Annals of Internal Medicine 95 (1981) 192-197
12. Purdue B.W., Tilakaratne N., and Sexton P.M. Molecular pharmacology of the calcitonin receptor. Receptors and Channels 8 (2002) 243-255
13. Raue F., Schmidt-Gayk H., and Ziegler R. Tumor markers in C-cell cancer. Deutsche medizinische Wochenschrift (1946) 108 (1983) 283-287
14. Bockhorn M., Frilling A., Rewerk S., et al. Lack of elevated serum carcinoembryonic antigen and calcitonin in medullary thyroid carcinoma. Thyroid 14 (2004) 468-470
15. Christensen S.B., Ljungberg O., and Tibblin S. A clinical epidemiologic study of thyroid carcinoma in Malmo, Sweden. Current Problems in Cancer 8 (1984) 1-49
16. Pacini F., Fontanelli M., Fugazzola L., et al. Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma. The Journal of Clinical Endocrinology and Metabolism 78 (1994) 826-829
17. Bergholm U., Adami H.O., Telenius-Berg M., et al. Incidence of sporadic and familial medullary thyroid carcinoma in Sweden 1959 through 1981. A nationwide study in 126 patients. Swedish MCT Study Group. Acta Oncologica 29 (1990) 9-15
18. Bondeson L., and Ljungberg O. Occult thyroid carcinoma at autopsy in Malmo, Sweden. Cancer 47 (1981) 319-323
19. Bhattacharyya N. A population-based analysis of survival factors in differentiated and medullary thyroid carcinoma. Otolaryngology and Head and Neck Surgery 128 (2003) 115-123
20. Mulligan L.M., Kwok J.B., Healey C.S., et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363 (1993) 458-460
21. Donis-Keller H., Dou S., Chi D., et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Human Molecular Genetics 2 (1993) 851-856
22. Santoro M., and Carlomagno F. Drug insight: small-molecule inhibitors of protein kinases in the treatment of thyroid cancer. Nature Clinical Practice 2 (2006) 42-52
23. Romei C., Elisei R., Pinchera A., et al. Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. The Journal of Clinical Endocrinology and Metabolism 81 (1996) 1619-1622
24. Zedenius J., Larsson C., Bergholm U., et al. Mutations of codon 918 in the RET proto-oncogene correlate to poor prognosis in sporadic medullary thyroid carcinomas. The Journal of Clinical Endocrinology and Metabolism 80 (1995) 3088-3090
25. Elisei R., Cosci B., Romei C., et al. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. The Journal of Clinical Endocrinology and Metabolism 93 (2008) 682-687
26. Hazard J.B., Hawk W.A., and Crile Jr. G. Medullary (solid) carcinoma of the thyroid; a clinicopathologic entity. The Journal of Clinical Endocrinology and Metabolism 19 (1959) 152-161
27. Melvin K.E., and Tashjian Jr. A.H. The syndrome of excessive thyrocalcitonin produced by medullary carcinoma of the thyroid. Proceedings of the National Academy of Sciences of the United States of America 59 (1968) 1216-1222
28. Christensen S.B., and Ljungberg O. Mortality from thyroid carcinoma in Malmo, Sweden 1960-1977. A clinical and pathologic study of 38 fatal cases. Cancer 54 (1984) 1629-1634
29. Kebebew E., Ituarte P.H., Siperstein A.E., et al. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 88 (2000) 1139-1148
30. Gharib H., McConahey W.M., Tiegs R.D., et al. Medullary thyroid carcinoma: clinicopathologic features and long-term follow-up of 65 patients treated during 1946 through 1970. Mayo Clinic proceedings 67 (1992) 934-940
31. Baloch Z.W., and LiVolsi V.A. Fine-needle aspiration of thyroid nodules: past, present, and future. Endocrine Practice 10 (2004) 234-241
32. Soderstrom N., Telenius-Berg M., and Akerman M. Diagnosis of medullary carcinoma of the thyroid by fine needle aspiration biopsy. Acta Medica Scandinavica 197 (1975) 71-76
33. Mendonca M.E., Ramos S., and Soares J. Medullary carcinoma of thyroid: a re-evaluation of the cytological criteria of diagnosis. Cytopathology 2 (1991) 93-102
34. Takeichi N., Ito H., Okamoto H., et al. The significance of immunochemically staining calcitonin and CEA in fine-needle aspiration biopsy materials from medullary carcinoma of the thyroid. The Japanese Journal of Surgery 19 (1989) 674-678
35. Papaparaskeva K., Nagel H., and Droese M. Cytologic diagnosis of medullary carcinoma of the thyroid gland. Diagnostic Cytopathology 22 (2000) 351-358
36. Forrest C.H., Frost F.A., de Boer W.B., et al. Medullary carcinoma of the thyroid: accuracy of diagnosis of fine-needle aspiration cytology. Cancer 84 (1998) 295-302
37. Rieu M., Lame M.C., Richard A., et al. Prevalence of sporadic medullary thyroid carcinoma: the importance of routine measurement of serum calcitonin in the diagnostic evaluation of thyroid nodules. Clinical Endocrinology 42 (1995) 453-460
38. Niccoli P., Wion-Barbot N., Caron P., et al. Interest of routine measurement of serum calcitonin: study in a large series of thyroidectomized patients. The French medullary study group. The Journal of Clinical Endocrinology and Metabolism 82 (1997) 338-341
39. Vierhapper H., Raber W., Bieglmayer C., et al. Routine measurement of plasma calcitonin in nodular thyroid diseases. The Journal of Clinical Endocrinology and Metabolism 82 (1997) 1589-1593
40. Kaserer K., Scheuba C., Neuhold N., et al. C-cell hyperplasia and medullary thyroid carcinoma in patients routinely screened for serum calcitonin. The American Journal of Surgical Pathology 22 (1998) 722-728
41. Ozgen A.G., Hamulu F., Bayraktar F., et al. Evaluation of routine basal serum calcitonin measurement for early diagnosis of medullary thyroid carcinoma in seven hundred seventy-three patients with nodular goiter. Thyroid 9 (1999) 579-582
42. Hahm J.R., Lee M.S., Min Y.K., et al. Routine measurement of serum calcitonin is useful for early detection of medullary thyroid carcinoma in patients with nodular thyroid diseases. Thyroid 11 (2001) 73-80
43. Bugalho M.J., Santos J.R., and Sobrinho L. Preoperative diagnosis of medullary thyroid carcinoma: fine needle aspiration cytology as compared with serum calcitonin measurement. Journal of Surgical Oncology 91 (2005) 56-60
44. Kini S.R., Miller J.M., Hamburger J.I., et al. Cytopathologic features of medullary carcinoma of the thyroid. Archives of Pathology and Laboratory Medicine 108 (1984) 156-159
45. Pacini F., Schlumberger M., Dralle H., et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. European Journal of Endocrinology / European Federation of Endocrine Societies 154 (2006) 787-803
46. Cooper D.S., Doherty G.M., Haugen B.R., et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16 (2006) 109-142
47. Machens A., Gimm O., Ukkat J., et al. Improved prediction of calcitonin normalization in medullary thyroid carcinoma patients by quantitative lymph node analysis. Cancer 88 (2000) 1909-1915
48. Elisei R., Bottici V., Luchetti F., et al. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. The Journal of Clinical Endocrinology and Metabolism 89 (2004) 163-168
49. Vierhapper H., Niederle B., Bieglmayer C., et al. Early diagnosis and curative therapy of medullary thyroid carcinoma by routine measurement of serum calcitonin in patients with thyroid disorders. Thyroid 15 (2005) 1267-1272
50. Borget I., De Pouvourville G., and Schlumberger M. Editorial: Calcitonin determination in patients with nodular thyroid disease. The Journal of Clinical Endocrinology and Metabolism 92 (2007) 425-427
51. Cheung K., Roman S.A., Wang T.S., et al. Calcitonin measurement in the evaluation of thyroid nodules in the United States: a cost-effectiveness and decision Analysis. The Journal of Clinical Endocrinology and Metabolism 93 (2008) 2173-2180
52. Tsolakis A.V., Portela-Gomes G.M., Stridsberg M., et al. Malignant gastric ghrelinoma with hyperghrelinemia. The Journal of Clinical Endocrinology and Metabolism 89 (2004) 3739-3744
53. Niccoli P., Conte-Devolx B., Lejeune P.J., et al. Hypercalcitoninemia in conditions other than medullary cancers of the thyroid. Annales d'endocrinologie 57 (1996) 15-21
54. Samaan N.A., Castillo S., Schultz P.N., et al. Serum calcitonin after pentagastrin stimulation in patients with bronchogenic and breast cancer compared to that in patients with medullary thyroid carcinoma. The Journal of Clinical Endocrinology and Metabolism 51 (1980) 237-241
55. Mullerpatan P.M., Joshi S.R., Shah R.C., et al. Calcitonin-secreting tumor of the pancreas. Digestive Surgery 21 (2004) 321-324
56. Guyetant S., Wion-Barbot N., Rousselet M.C., et al. C-cell hyperplasia associated with chronic lymphocytic thyroiditis: a retrospective quantitative study of 112 cases. Human Pathology 25 (1994) 514-521
57. Albores-Saavedra J., Monforte H., Nadji M., et al. C-cell hyperplasia in thyroid tissue adjacent to follicular cell tumors. Human Pathology 19 (1988) 795-799
58. Scopsi L., Di Palma S., Ferrari C., et al. C-cell hyperplasia accompanying thyroid diseases other than medullary carcinoma: an immunocytochemical study by means of antibodies to calcitonin and somatostatin. Modern Pathology 4 (1991) 297-304
59. Costante G., Meringolo D., Durante C., et al. Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. The Journal of Clinical Endocrinology and Metabolism 92 (2007) 450-455
60. Kudo T., Miyauchi A., Ito Y., et al. Diagnosis of medullary thyroid carcinoma by calcitonin measurement in fine-needle aspiration biopsy specimens. Thyroid 17 (2007) 635-638
61. Boi F., Maurelli I., Pinna G., et al. Calcitonin measurement in wash-out fluid from fine needle aspiration of neck masses in patients with primary and metastatic medullary thyroid carcinoma. The Journal of Clinical Endocrinology and Metabolism 92 (2007) 2115-2118
62. Engelbach M., Gorges R., Forst T., et al. Improved diagnostic methods in the follow-up of medullary thyroid carcinoma by highly specific calcitonin measurements. The Journal of Clinical Endocrinology and Metabolism 85 (2000) 1890-1894
63. Tommasi M., Brocchi A., Cappellini A., et al. False serum calcitonin high levels using a non-competitive two-site IRMA. Journal of Endocrinological Investigation 24 (2001) 356-360
64. Ichimura T., Kondo S., Okushiba S., et al. A calcitonin and vasoactive intestinal peptide-producing pancreatic endocrine tumor associated with the WDHA syndrome. International Journal of Gastrointestinal Cancer 33 (2003) 99-102
65. Karanikas G., Moameni A., Poetzi C., et al. Frequency and relevance of elevated calcitonin levels in patients with neoplastic and nonneoplastic thyroid disease and in healthy subjects. The Journal of Clinical Endocrinology and Metabolism 89 (2004) 515-519
66. Barbot N., Calmettes C., Schuffenecker I., et al. Pentagastrin stimulation test and early diagnosis of medullary thyroid carcinoma using an immunoradiometric assay of calcitonin: comparison with genetic screening in hereditary medullary thyroid carcinoma. The Journal of Clinical Endocrinology and Metabolism 78 (1994) 114-120
67. Perry A., Molberg K., and Albores-Saavedra J. Physiologic versus neoplastic C-cell hyperplasia of the thyroid: separation of distinct histologic and biologic entities. Cancer 77 (1996) 750-756
68. Barbot N., Guyetant S., Beldent V., et al. Chronic autoimmune thyroiditis and C-cell hyperplasia. Study of calcitonin secretion in 24 patients. Annales d'endocrinologie 52 (1991) 109-112
69. Morgan K.G., and Szurszewski J.H. Mechanisms of phasic and tonic actions of pentagastrin on canine gastric smooth muscle. The Journal of Physiology 301 (1980) 229-242
70. Schuurkes J.A., and Charbon G.A. Motility and hemodynamics of the canine gastrointestinal tract. Stimulation by pentagastrin, cholecystokinin and vasopressin. Archives internationales de pharmacodynamie et de therapie 236 (1978) 214-227
71. Hulstaert P.F., Geurts W.J., Brouwer F.A., et al. Hemodynamic actions of pentagastrin. Scandinavian Journal of Gastroenterology 15 (1980) 7-15
72. Ewers H.R., Brouwers H.P., Merguet P., et al. Side effects after stimulation of gastric secretion with pentagastrin (author's transl). Medizinische Klinik 71 (1976) 19-23